842 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
.
In the first quarter of 2024, we recognized a tax benefit of $52 million, on a pre-tax loss of $467 million. In the first quarter of 2023, we recognized … a tax benefit of $19 million, on a pre-tax loss of $272 million. Our tax rate for the first quarter of 2024 was mainly affected by deferred tax benefits
8-K
EX-99.1
h6lqowxg3 bh38
31 Jan 24
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
qe2okk y0csrrzk58
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
EX-10.1
ypqqg
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
6oxafs5
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
0ypdhlc59ucv8k3bcvj
10 May 23
Results of Operations and Financial Condition
7:01am
CORRESP
ukit9 eztku
20 Dec 22
Correspondence with SEC
12:00am
8-K
2n9pkftcyg8nh 6c8
21 Nov 22
Teva Announces Appointment of Richard Francis as President and CEO
7:00am
8-K
EX-99.1
5fxb293td8f38pxplt
3 Nov 22
Key financial highlights and outlook
7:00am